150 related articles for article (PubMed ID: 411754)
1. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
Sensakovic JW; Bartell PF
Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
[TBL] [Abstract][Full Text] [Related]
2. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
Lieberman MM; McKissock DC; Wright GL
Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
[TBL] [Abstract][Full Text] [Related]
3. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
4. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
[TBL] [Abstract][Full Text] [Related]
5. Polysaccharide of the slime glycolipoprotein of Pseudomonas aeruginosa.
Koepp LH; Orr T; Bartell PF
Infect Immun; 1981 Sep; 33(3):788-94. PubMed ID: 6793519
[TBL] [Abstract][Full Text] [Related]
6. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
Fisher MW
J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
[TBL] [Abstract][Full Text] [Related]
9. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
Moody MR; Kessel RW; Young VM; Fiset P
Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
[TBL] [Abstract][Full Text] [Related]
10. Influence of anti-slime glycolipoprotein serum on the interaction between Pseudomonas aeruginosa and macrophages.
Bartell PF; Krikszens A
Infect Immun; 1980 Mar; 27(3):777-83. PubMed ID: 6769808
[TBL] [Abstract][Full Text] [Related]
11. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
Jones RJ; Hall M; Ricketts CR
Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
[TBL] [Abstract][Full Text] [Related]
12. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
Mates A; Zand P
J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
[TBL] [Abstract][Full Text] [Related]
13. Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.
Berk RS; Montgomery IN; Hazlett LD
Infect Immun; 1988 Dec; 56(12):3076-80. PubMed ID: 3141279
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa infection and vaccination in the rat.
Kostiala AA
J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
[TBL] [Abstract][Full Text] [Related]
15. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study of the dynamics of the formation of protective antibodies to the antigens of the slime of Pseudomonas aeruginosa].
Iushkova NA; Stanislavskiĭ ES; Landsman NM
Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):78-83. PubMed ID: 6405564
[TBL] [Abstract][Full Text] [Related]
17. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
18. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
19. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
[TBL] [Abstract][Full Text] [Related]
20. Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa.
Jones RJ
Br J Exp Pathol; 1968 Oct; 49(5):411-20. PubMed ID: 4973304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
